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Introduction
Many Chinese medicinal products have been traditionally 
used for the treatment of cardiovascular diseases, and their 
curative effects have also been verified by a large number of 
clinical studies in the past few decades[1, 2].  A large number 
of these Chinese medicinal products seem to achieve their 
therapeutic effects via the promotion of blood circulation. 
Promoting blood circulation, including improvement of hemo-
dynamic and hemorheology, and removing blood stasis, are 
already accepted concept in Traditional Chinese Medicine. 
However, little is known for the detailed molecular mecha-
nisms how these Chinese medicines trigger the promotion of 
blood circulation.
Cardiac glycosides, such as ouabain and digoxin, are steroid-
like compounds and have been used in the treatment of con-
gestive heart failure and supraventricular arrhythmias.  The 
therapeutic effect of cardiac glycosides lies in their reversible 
inhibition on the membrane-bound Na+/K+-ATPase located 
in human myocardium[3].  The inhibition on Na+/K+-ATPase 
leads to the elevation of intracellular Na+ concentration, which 
in turn activates a Na+ /Ca2+ exchanger resulting in an increase 
of intracellular Ca2+ concentration.  The elevated intracellular 
Ca2+ concentration causes an increased inotropism, accentu-
ating the force of myocardial contraction by increasing the 
velocity and extent of sarcomere shortening, thus translating 
into increased stroke work for a given filling volume of pres-
sure.
Biosynthesis of steroid-like compounds proceeds from the 
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cyclization of oxidosqualene in the isoprenoid pathway.  After 
rearrangement and additional modifications of the carbon 
skeleton, three major end products, tetracyclic triterpenoids, 
pentacyclic triterpenoids and steroids are yielded.  These 
structurally similar compounds are converted to saponins via 
sugar attachment at variable positions of their carbon skeleton, 
usually C-3 position.  The core structure of cardiac glycosides 
consists of a tetracyclic steroidal framework, which is consid-
ered the pharmacophoric moiety responsible for their inhibi-
tion on Na+/K+-ATPase[4].  Amusingly, a number of steroid-
like compounds, such as triterpenoids, steroids and saponins, 
are also found in many Chinese medicinal products used for 
promoting blood circulation, and regarded as the active ingre-
dients responsible for their therapeutic effects[5].  
In a previous study, we demonstrated that ginsenosides 
with sugar moieties attached only to the C-3 position of their 
core steroid-like structure possessed inhibitory potency on 
Na+/K+-ATPase activity, and the inhibition was proposed 
to be partly, at least, responsible for the cardiac therapeu-
tic effects of ginseng and sanqi via the promotion of blood 
circulation[6].  Therefore, we wonder if various steroid-like 
compounds found in other Chinese medicinal products may 
promote blood circulation via the same molecular mechanism. 
In this study, Na+/K+-ATPase inhibition by ouabain, ginseno-
side Rh2 and several steroid-like compounds found in Chinese 
medicinal products used for promoting blood circulation was 
examined and compared.  Molecular modeling and docking of 
these compounds to Na+/K+-ATPase were exhibited to reveal 
the observed difference in their inhibitory potency at molecu-
lar level.  
Materials and methods
Chemicals and reagents 
Ginsenoside Rh2, polygalacic acid and jujuboside B were pur-
chased from Scientific Pharmaceutical Elite Company (Taiwan, 
China).  Saikosaponin A and glycyrrhizin were purchased 
from Yoneyama Chemical Industry (Japan).  Sarsasapogenin 
and astragaloside III were purchased from ChromaDex (USA). 
Bufalin was obtained from Wako Pure Chemical Industries 
(Japan).  Ursolic acid, oleanolic acid, cholic acid, and ouabain 
were obtained from Sigma (USA).  Phosphate assay kit was 
purchased from Amresco (USA).
Measurement of Na+/K+-ATPase activity 
The activity of Na+/K+-ATPase was determined by measuring 
the amount of inorganic phosphate (Pi) liberated from ATP. 
A commercial Na+/K+-ATPase from porcine cerebral cortex 
(Sigma, 0.3 units/mg) was incorporated into a reaction mix-
ture of 500 μL containing 1 mmol/L ATP, 5 mmol/L MgCl2, 
80 mmol/L NaCl, 20 mmol/L KCl, and 40 mmol/L Tris-HCl 
(pH 7.8); the enzymatic reaction was terminated by adding 
250 µL of 30% (w/v) trichloroacetic acid after the incubation 
period.  After centrifugation at 10 000×g for 10 min at 4 °C, the 
supernatant was diluted 12.5-fold with deionized water and 
then added with 50 μL color development reagent provided 
by the phosphate assay kit.  After 30 min of incubation at 
room temperature, the color intensity was measured at 620 nm 
on SpectraMax M2 reader (Molecular Devices, USA).  Sodium 
pump activity was expressed as μmol Pi liberated from ATP 
by 1 mg of Na+/K+-ATPase in 1 h.  
Statistical analysis 
Data were expressed as mean±SEM of 5 replicates and the 
analysis of variance (One-way ANOVA) was performed on 
SPSS 12.0 for Windows.  Differences were considered statisti-
cally significant at P<0.05.  
Molecular modeling and docking 
The crystal structures of pig renal Na+,K+-ATPase (PDB code 
3B8E) and shark rectal gland Na+,K+-ATPase (PDB code 
3A3Y) were downloaded from Protein Data Bank and found 
to posses equivalent structures[7, 8].  In order to facilitate dock-
ing process, the β and γ subunits of the Na+,K+-ATPase were 
removed, as well as the water molecules and counter-ions 
surrounding the remaining α subunit.  The modified Na+,K+-
ATPase after hydrogen saturation was minimized with 
CHARMm force field[9] using the Discover Studio 2.0 package 
(http://accelrys.com/products/discovery-studio/).  The 2D 
structures of ginsenosides used in this study were constructed 
by using the ChemDraw program, and their corresponding 3D 
structures were converted by the Chem3D program (http://
www.cambridgesoft.com/).  The pocket for binding cardiac 
glycosides in the Na+,K+-ATPase α subunit was defined among 
the extracellular loops linking transmembrane segments as 
reported by Qiu et al[10], and the subunit-binding domain was 
defined as the region of the sphere with 10 Å radius from the 
center of the binding pocket, which lies between Ile315 and 
Leu793 of the modified Na+,K+-ATPase.  Docking of steroid-
like compounds was performed in silico by employing the Lib-
Dock module[11] in the Discover Studio 2.0 package.  There are 
100 hotspots identified in the binding pocket.  The LibDock 
methodology effectively executed the docking of combina-
torial libraries of compounds in a high throughput manner 
while keeping the protein structure fixed[12].  After LibDock, 
the protein-ligand complexes were further optimized by 
LigandFit and then smart minimizer algorithm to minimize 
with CHARMm forcefield.  Among the candidate structures, 
reported by the docking simulation, the docking structure 
with highest Ligscore2 value, as computed by the score ligand 
pose module, was selected to represent each of those steroid-
like compounds inside the binding pocket.  
Results
Steroid-like compounds in Chinese medicinal products used for 
promoting blood circulation 
Eleven steroid-like compounds were selected for this study as 
they have been structurally determined and regarded as pos-
sible active ingredients in Chinese medicinal products used 
for the promotion of blood circulation and the treatment of 
cardiovascular diseases (Table 1)[13–23].  These 11 steroid-like 
compounds are structurally similar to ouabain, a cardiac gly-
coside, in the hydrophobic steroidal core regardless the differ-
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ent sugar units attached to the C-3 position and diverse oxida-
tive groups modified at variable positions (Figure 1).  
Inhibition of Na+,K+-ATPase by the selected steroid-l ike 
compounds 
To examine whether the selected steroid-like compounds from 
Chinese medicinal herbs may be responsible for the effect of 
promoting blood circulation via the same mechanism trig-
gered by ouabain, a commercial Na+,K+-ATPase from porcine 
cerebral cortex was used to evaluate the inhibitory potency of 
these compounds.  All the examined steroid-like compounds 
displayed more or less inhibition on Na+/K+-ATPase in a 
dose-dependent manner (Figure 2).  Among these steroid-
like compounds, bufalin (structurally almost equivalent to 
ouabain with a unique lactone ring attached to the hydropho-
bic steroidal core) exhibited significantly higher inhibitory 
potency than the others.  In the five examined pentacyclic 
triterpenoids, ursolic acid and oleanolic acid were detected as 
moderate inhibitors of Na+/K+-ATPase while saikosaponin A, 
polygalacic acid and glycyrrhizin only exhibited weak inhibi-
tion.  The IC50 of ursolic acid (76.7 µmol/L) or oleanolic acid 
(94.3 µmol/L) was comparable to that of ginsenoside Rh2 (37.5 
µmol/L) (Figure 3).  
Figure 1.  Chemical structures of ouabain and 11 steroid-like compounds found in Chinese medicinal products used for the promotion of blood 
circulation.
Table 1.  Steroid-like compounds in Chinese medicines used for the promotion of blood circulation.
        Compound                                                            Chinese medicinal sources                                                                                           References 
 
 Bufalin The dried venom of Bufo bufo gargarizans Cantor or B bufo melanostictus Schneider 13
 Ginsenoside Rh2 The dry root of Panax ginseng or P notoginseng FH Chen 14
 Ursolic acid Whole plant of Prunella vulgaris L with dry flowers 15
 Oleanolic acid Whole plant of Prunella vulgaris L with dry flowers 15
 Saikosaponin A The dry root of Bupleurum chinense DC or B scorzonerifolium Willd 16, 17
 Cholic acid The dried bile of Ursus arctos Linnaeus or Selenarctos thibetanus G Cuvier 18
 Sarsasapogenin The dry root of Anemarrhena asphodeloides Bge 19
 Polygalacic acid The dry root of Platycodon grandiflorum (Jacq) A DC 20
 Jujuboside B The mature seeds of Ziziphus jujube Mill var spinosa (Bunge) Hu ex HF Chou 21
 Glycyrrhizin The root of Glycyrrhiza uralensis Fisch G inflata Bat or G glabra L 17, 22
 Astragaloside III The dry root of Astragalus membranaceus (Fisch) Bge or var mongholicus (Bge) Hsiao 23
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Molecular modeling and docking of steroid-like compounds to 
Na+,K+-ATPase 
To reveal the observed difference in Na+,K+-ATPase inhibition 
at molecular level, the examined steroid-like compounds were 
subjected to molecular modeling and docking, as exempli-
fied by bufalin and ursolic acid, to the extracellular domain 
of Na+,K+-ATPase α subunit.  As expected from structural 
similarity, the interaction of bufalin with the binding pocket 
of Na+,K+-ATPase nearly matched to that of ouabain reported 
previously[7] with the unique lactone ring (indicated by a pink 
arrow) penetrating deeply into the cavity close to two K+ bind-
ing sites (Figure 4A).  Comparably, the hydrophobic steroidal 
core of ursolic acid was confined in a location similar to that 
of bufalin within the binding pocket of Na+,K+-ATPase (Figure 
4B).  However, no hydrophilic functional group attached to 
the hydrophobic steroidal core of ursolic acid was present in 
the location equivalently occupied by the lactone ring of bufa-
lin in the deep cavity close to two K+ binding sites of Na+,K+-
ATPase.
In accord with the results of Na+,K+-ATPase inhibition assay 
for the examined pentacyclic triterpenoids, the relatively high 
inhibitory potency of ursolic acid or oleanolic acid is due to 
the formation of a hydrogen bond between its carboxyl group 
at C-17 and the Ile322 residue in the deep cavity close to two 
K+ binding sites of Na+/K+-ATPase (Figure 5).  This hydrogen 
bond is not found in the other three pentacyclic triterpenoids, 
saikosaponin A, polygalacic acid and glycyrrhizin, neither 
in another pentacyclic steroid-like compound, jujuboside B. 
The carboxyl group of ursolic acid or oleanolic acid forming 
a hydrogen bond with Ile322 of Na+/K+-ATPase is also cor-
respondingly present in polygalacic acid; however, an intra-
molecular hydrogen bond between the carboxyl group and 
an adjacent hydroxyl group at C-16 is formed in polygalacic 
acid (indicated by a pink box) and impedes its formation of 
the intermolecular hydrogen bond with Na+/K+-ATPase.  In 
contrast, a different hydrogen bond is formed between the 
carboxyl group of glycyrrhizin and Ala330 of Na+/K+-ATPase 
(indicated by a green box).  Whereas, the repulsion between 
the hydrophilic carbonyl group at C-11 of glycyrrhizin and 
the hydrophobic Ile322 and Phe323 of Na+/K+-ATPase (indi-
cated by two purple boxes) greatly reduces the stability of 
Figure 2.  (A) Inhibition of porcine Na+,K+-ATPase by 0.1 mmol/L of 
ouabain and the selected 11 steroid-like compounds.  (B) For the 7 
compounds showing low inhibitory potency, the concentration was 
increased to 0.2 mmol/L for the same assay.  Inhibitory potency of these 
compounds, presented in the order as shown in Figure 1, was observed 
as the reduction of Pi liberation released from ATP by a constant amount 
of commercial porcine Na+,K+-ATPase.  Data represent mean±SEM of 5 
replicates.  bP<0.05, cP<0.01 vs control group (CON; deionized water only).
Figure 3.  Inhibitory potency of ginsenoside Rh2, ursolic acid (UA) and 
oleanolic acid (OA) on porcine Na+,K+-ATPase.  Inhibitory potency of 
various concentrations of ginsenoside Rh2, ursolic acid and oleanolic 
acid was observed as the reduction of Pi liberation released from ATP by a 
constant amount of commercial porcine Na+,K+-ATPase.
Figure 4.  Modeling of bufalin (A) and ursolic acid (B) binding to the 
extracellular pocket of Na+,K+-ATPase α subunit.  The amino acid residues 
around the binding pocket of Na+,K+-ATPase are shown in ribbon structure, 
and bufalin and ursolic acid in scaled ball and stick.  Three K+ binding 
sites are shown in purple balls.  The position of the unique lactone ring of 
bufalin is indicated by a pink arrow. 
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glycyrrhizin-Na+/K+-ATPase complex.  As expected from the 
inhibition assay and chemical structures, no hydrogen bond 
is formed between Na+/K+-ATPase and cholic acid, sarsaspo-
genin or astragaloside III (data not shown).
Regardless of their structural similarity and functional 
capability of inhibiting Na+/K+-ATPase activity, drastic dif-
ference was observed in the inhibitory potency of ouabain, 
bufalin, ginsenoside Rh2, and ursolic acid (Figure 2).  The 
difference is ascribed mainly to the number of hydrogen 
bonds (H-bonds) and partially to the strength of hydropho-
bic interaction between the compounds and residues around 
the deep cavity close to the two K+ binding sites of Na+/K+- 
ATPase (Figure 6).  Three H-bonds are formed between the 
lactone of ouabain and Ile328 (forming one H-bond) and 
Ala330 (forming two H-bonds) of Na+/K+-ATPase, and two 
H-bonds between the hydroxyl group at C-14 of ouabain and 
Thr804 of Na+/K+-ATPase.  In contrast, one H-bond is formed 
between the lactone of bufalin and Ala330 of Na+/K+-ATPase, 
and two H-bonds between the hydroxyl group at C-14 of 
bufalin and Thr804 of Na+/K+-ATPase.  Strong hydrophobic 
interaction is found between the lactone of ouabain or bufalin 
and six hydrophobic residues (Ile327, Ile328, Val329, Ile787, 
Phe790, and Ile807 shown in spacefill) around the deep cavity 
of Na+/K+-ATPase.  Two H-bonds are formed between the 
hydroxyl groups at C-12 and C-20 of ginsenoside Rh2 and 
Asn129 and Thr804 of Na+/K+-ATPase, respectively; and 
strong hydrophobic interaction is found between the alkyl 
group of ginsenoside Rh2 and the same six hydrophobic 
residues around the deep cavity of Na+/K+-ATPase.  One 
H-bond is formed between the carboxyl group of ursolic acid 
and Ile322 of Na+/K+-ATPase, and moderate hydrophobic 
Figure 5.  Detailed molecular interactions between the extracellular pocket 
of Na+,K+-ATPase and ursolic acid (UA), oleanolic acid (OA), saikosaponin 
A (Sai), polygalacic acid (PA), glycyrrhizin (Gly), and jujuboside B (Juj).  The 
amino acid residues of Na+,K+-ATPase close to the binding compounds 
are shown in wireframe, and the structures of the compounds in scaled 
ball and stick.  A hydrogen bond formed between Na+,K+-ATPase and 
ursolic acid, oleanolic acid or glycyrrhizin is indicated by a green box.  An 
intramolecular hydrogen bond in polygalacic acid is indicated by a pink 
box.  The repulsion between the hydrophilic carbonyl group of glycyrrhizin 
and the hydrophobic Ile322 and Phe323 of Na+/K+-ATPase is indicated by 
two purple boxes.
Figure 6.  Detailed molecular interactions between the extracellular 
binding pocket of Na+,K+-ATPase and ouabain (Oua), bufalin (Buf), 
ginsenoside Rh2, and ursolic acid (UA).  The hydrophobic amino acid 
residues around the deep cavity of Na+,K+-ATPase interacting with the 
binding compounds are shown in spacefill, the rest of amino acid residues 
of Na+,K+-ATPase close to the binding compounds in wireframe, and the 
compounds in scaled ball and stick.  The hydrogen bonds formed between 
Na+,K+-ATPase and the compounds are indicated by green boxes.  
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interaction is found between the ring E of ursolic acid and 
four hydrophobic residues (Ile327, Val329, Phe790, and Ile807 
shown in spacefill) of Na+/K+-ATPase.  In addition, similar 
hydrophobic interaction is observed between the hydropho-
bic steroidal core of each examined compound and 8 other 
hydrophobic residues (Leu132, Tyr315, Ile322, Phe323, Ile325, 
Phe793, Ile794, and Leu802 located in the upper portions of 
the figures shown in wireframe) around the binding pocket of 
Na+/K+-ATPase.
Discussion
On the basis of this study, the therapeutic effects of many 
cardiac Chinese medicinal products may be partly, at least, 
attributed to various steroid-like compounds that promote 
blood circulation via the same molecular mechanism triggered 
by ouabain, that is, accentuating the force of myocardial con-
traction by elevating calcium concentration via the inhibition 
of Na+,K+-ATPase.  Bufalin, the active but toxic component 
in Chansu (a traditional Chinese medicine used to rescue 
patients with heart failure) has a chemical structure highly 
similar to ouabain, particularly with a unique lactone ring 
attached to the hydrophobic steroidal core, and thus possesses 
strong inhibitory potency on Na+,K+-ATPase.  Comparable to 
ginsenosides as reported previously[6], ursolic acid and oleano-
lic acid are moderate inhibitors of Na+,K+-ATPase among the 
examined pentacyclic triterpenoids, possessing IC50 approxi-
mately 100 times higher than that of ouabain.  It seems that 
detection of inhibitory potency on Na+,K+-ATPase together 
with the theoretical modeling of docking may be a suitable 
platform for the first screening of potential drug compounds 
from the abundant sources of Chinese medicinal products tra-
ditionally used for the treatment of cardiovascular diseases.
Ursolic acid and oleanolic acid are widely present in food, 
medicinal herbs and other plants[24].  So far, most pharmaco-
logical investigation of these two pentacyclic triterpenoids 
focused on their anti-inflammatory, anti-hyperlipidemic and 
hepatoprotective properties[25, 26].  The early understanding of 
their anti-inflammatory and hepatoprotective properties facili-
tated their use as remedies for the treatment of liver-related 
pathologies.  In light of the results shown in this study, we 
propose that ursolic acid and oleanolic acid may also possess 
cardiac therapeutic effects as a consequence of their inhibitory 
potency on Na+,K+-ATPase.  
Prunella vulgaris L, a commonly used Chinese medicinal 
herb, also known as self-heal, has a wide range of reported 
medicinal activities[27, 28].  This herb with antioxidant, antimi-
crobial and anti-inflammatory properties has a long history of 
use as a remedy for cardiovascular diseases[29, 30].  Phytochemi-
cal analyses showed that ursolic acid, oleanolic acid and their 
glycoside derivatives were the major components of P vulgaris 
L[31].  Commonly, the glycoside derivatives tend to be metabo-
lized to their aglycone by intestinal bacterial deglycosyla-
tion after oral administration, and the metabolites are easily 
absorbed by the intestines due to the increase of hydropho-
bicity[32,33].  Therefore, it is likely that the cardiac therapeutic 
effects of P vulgaris L are partly, at least, attributed to the effec-
tive inhibition of Na+,K+-ATPase by their major triterpenoidal 
ingredients, ursolic acid and oleanolic acid as well as their 
glycoside derivatives.  Similarly, ginsenoside Ro, an oleanolic 
acid glycoside may partly contribute to the cardiac therapeutic 
effect of ginseng after deglycosylation by intestinal bacteria[34].
Experimental observation and theoretical modeling revealed 
that an oxygen-containing function group attached to ring C 
or D of steroid-like compounds is crucial for their inhibitory 
potency on Na+,K+-ATPase, ie, the oxidized functional group 
may form hydrogen bonds with Na+,K+-ATPase within the 
binding pocket very close to the K+ binding sites.  As shown 
in this study, the carboxyl group of ursolic acid or oleanolic 
acid, the hydroxyl group at C-14 of ouabain or bufalin, and the 
hydroxyl groups at C-12 of ginsenoside Rh2 formed hydro-
gen bonds with Na+,K+-ATPase.  On the other hand, lactone 
ring of ouabain and bufalin is definitely the key moiety to 
their potent inhibition on Na+,K+-ATPase, hence the steroid-
like compounds attached with flexible functional group 
structurally similar to lactone at ring D could be selected as 
potent inhibitors of Na+,K+-ATPase.  The moiety connected 
to ring D of steroid-like compound should be the target of 
chemical modification for increasing its inhibitory potency on 
Na+,K+-ATPase.  Although our experimental observation and 
theoretical modeling were executed using porcine and shark 
Na+,K+-ATPase, the observed inhibitory potency of steroid-
like compounds was presumably applicable to human Na+,K+-
ATPase since isoforms of this enzyme in diverse species were 
highly conserved throughout evolution[35].  Of course, the pre-
cise interaction of the steroid-like compounds in the binding 
pocket of Na+,K+-ATPase should be further elucidated by their 
co-crystal 3D structure.  
More and more evidence supports that Na+,K+-ATPase can 
be a drug target for the treatment of several diseases, includ-
ing congestive heart failure, ischemic stroke, neurodegenera-
tive diseases and even cancer[36].  Recently several compounds 
showing inhibitory potency on Na+,K+-ATPase, such as cardiac 
glycosides, ginsenosides, and magnesium lithospermate B (the 
major water soluble ingredient in the dried roots of medicinal 
plant Salvia miltiorrhiza), were demonstrated to provide neu-
roprotection against ischemic stroke in a cortical brain slice-
based compound screening platform[6, 37, 38].  Similarly, oleano-
lic acid, showing inhibitory potency on Na+,K+-ATPase in this 
study, has also been demonstrated to display neuroprotective 
effect against focal cerebral ischemic injury[39].  The cumulated 
evidence suggests that inhibiting Na+,K+-ATPase may provide 
neuroprotection in the context of ischemia as well as other 
neurodegenerative conditions though it cannot be ignored 
that the neuroprotective effects of those compounds against 
cerebral ischemic injury may be partly attributed to their anti-
oxidative properties.  Moreover, it has been hypothesized that 
blockade of Na+,K+-ATPase may provide neuroprotection in 
ischemia through ATP conservation and modulating intracel-
lular calcium levels just as the cardiac glycosides do in the 
heart contraction cycle[40].
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